programmed death-ligand 1-targeted immune-stimulating antibody conjugate

A **programmed death-ligand 1-targeted immune-stimulating antibody conjugate** is a preclinical **PD-L1-directed immune-stimulating antibody conjugate** being developed by Bolt Biotherapeutics for cancer. It consists of a novel human anti-PD-L1 antibody conjugated through a non-cleavable linker to a next-generation TLR7/8 agonist payload, with the intended effect of localizing innate immune activation to PD-L1-expressing tumor and myeloid cells in the tumor microenvironment. Rather than representing a clearly disclosed, uniquely named clinical asset, the term is used generically by the company to describe its PD-L1 ISAC research program; available public information indicates preclinical antitumor activity and immune reprogramming in resistant tumor models, but no clearly identified marketed product, approved indication, or widely established canonical code name is publicly tied to this exact name.

Other names

PD-L1 ISACPD-L-1 ISACPD-L 1 ISACanti PD-L1 immune-stimulating antibody conjugate